Liminatus Pharma, Inc. Class A Common Stock (LIMN) - Total Liabilities
Based on the latest financial reports, Liminatus Pharma, Inc. Class A Common Stock (LIMN) has total liabilities worth $2.92 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Liminatus Pharma, Inc. Class A Common St current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liminatus Pharma, Inc. Class A Common Stock - Total Liabilities Trend (2021–2025)
This chart illustrates how Liminatus Pharma, Inc. Class A Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Liminatus Pharma, Inc. Class A Common St (LIMN) total assets.
Liminatus Pharma, Inc. Class A Common Stock Competitors by Total Liabilities
The table below lists competitors of Liminatus Pharma, Inc. Class A Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tapaco Public Company Limited
BK:TAPAC
|
Thailand | ฿942.67 Million |
|
Homebiogas Ltd
TA:HMGS
|
Israel | ILA2.20 Million |
|
Edgewater Wireless Systems Inc
V:YFI
|
Canada | CA$1.57 Million |
|
Mahaka Media Tbk
JK:ABBA
|
Indonesia | Rp354.46 Billion |
|
DY6 Metals Ltd
AU:DY6
|
Australia | AU$332.27K |
|
HYPERCHARGE NETWORKS CORP
F:PB7
|
Germany | €3.87 Million |
|
Scorpion Minerals Ltd
AU:SCN
|
Australia | AU$1.66 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Liminatus Pharma, Inc. Class A Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Liminatus Pharma, Inc. Class A Common St balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -22.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Liminatus Pharma, Inc. Class A Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Liminatus Pharma, Inc. Class A Common Stock (2021–2025)
The table below shows the annual total liabilities of Liminatus Pharma, Inc. Class A Common Stock from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $10.33 Million | -44.77% |
| 2024-12-31 | $18.70 Million | +23.06% |
| 2023-12-31 | $15.19 Million | +7.05% |
| 2022-12-31 | $14.19 Million | -34.20% |
| 2021-12-31 | $21.57 Million | -- |
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.